Enanta Pharmaceuticals Presents Data on a Novel Non-Fusion Inhibitor of Respiratory Syncytial Virus (RSV) at the 10th Annual ...
September 29 2016 - 4:06PM
Business Wire
- Lead compound shows promising
anti-viral activity in RSV-A and RSV-B
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and
development-focused biotechnology company dedicated to creating
small molecule drugs for viral infections and liver diseases, today
announced that a poster presentation on one of the lead compounds
in its RSV program was presented today at the 10th Annual
Respiratory Syncytial Virus conference taking place September 28
through October 1, in Patagonia, Argentina.
Data presented in a poster titled, EP-023938, A Novel Non-Fusion
Replication Inhibitor of Respiratory Syncytial Virus (RSV), M.H. J.
Rhodin, et al., demonstrated that EP-023938 is a potent inhibitor
of both RSV-A and RSV-B activity, maintaining antiviral activity
post-infection while presenting a high barrier to resistance.
Further, EP-023938 maintained antiviral potency across all clinical
isolates tested as well as virus that was resistant to fusion
inhibitors. Given this favorable preclinical profile, along with
demonstrated synergy with inhibitors of other mechanisms, Enanta
plans to continue evaluation of EP-023938 as a potential
development candidate for RSV.
EP-023938 is a non-fusion inhibitor and one of several
discovered by Enanta for potential development for RSV. Enanta
believes that its approach differentiates its compounds from fusion
inhibitors currently in development for RSV because its non-fusion
inhibitors directly target the virus replication machinery and have
demonstrated high barriers to resistance against the virus in
vitro. Additionally, non-fusion inhibitors have the potential of
being effective at later stages of infection.
The abstract can be viewed at http://www.rsv16.org/.
About RSVRespiratory syncytial virus (RSV) is a virus
that infects the lungs and represents a serious unmet medical need
in infants and children, as well as immune-compromised individuals
and the elderly. RSV is the most common cause of bronchiolitis
(inflammation of the small airways in the lung) and pneumonia in
children under 1 year of age in the United States. Each year,
75,000 to 125,000 children in this group are hospitalized due to
RSV infection. Children with compromised (weakened) immune systems
due to a medical condition or medical treatment, adults with
compromised immune systems and those 65 and older are also at
increased risk of severe disease. There is currently no effective
treatment available for treating RSV infection.
About EnantaEnanta Pharmaceuticals is a research and
development-focused biotechnology company that uses its robust
chemistry-driven approach and drug discovery capabilities to create
small molecule drugs for viral infections and liver diseases.
Enanta’s research and development efforts are currently focused on
four disease targets: Hepatitis C Virus (HCV), Hepatitis B Virus
(HBV), Non-alcoholic Steatohepatitis (NASH) and Respiratory
Syncytial Virus (RSV).
Enanta has discovered novel protease inhibitors and NS5A
inhibitors that are members of the direct-acting-antiviral (DAA)
inhibitor classes designed for use against the hepatitis C virus
(HCV). Enanta’s protease inhibitors, developed through its
collaboration with AbbVie, include paritaprevir, which is contained
in AbbVie’s marketed DAA regimens for HCV, and ABT-493, Enanta’s
second protease inhibitor, which AbbVie is developing in Phase 3
studies in combination with ABT-530, AbbVie’s NS5A inhibitor.
Enanta has also discovered a cyclophilin inhibitor, EDP-494, a
novel host-targeting mechanism for HCV, which is now in a clinical
proof of concept study in HCV patients, and EDP-305, a non-bile
acid FXR agonist for NASH, currently in Phase 1 clinical
development. Please visit www.enanta.com for more information on
our programs and pipeline.
Forward Looking Statements DisclaimerThis press release
contains forward-looking statements, including statements with
respect to the prospects for development of one of Enanta’s lead
compounds for the treatment of RSV. Statements that are not
historical facts are based on management’s current expectations,
estimates, forecasts and projections about Enanta’s business and
the industry in which it operates and management’s beliefs and
assumptions. The statements contained in this release are not
guarantees of future performance and involve certain risks,
uncertainties and assumptions, which are difficult to predict.
Therefore, actual outcomes and results may differ materially from
what is expressed in such forward-looking statements. Important
factors and risks that may affect actual results include: the
development risks of early stage discovery efforts in disease areas
such as RSV that have no current therapeutic treatment; potential
competition from the development efforts of others in this disease
area; Enanta’s lack of clinical development experience; Enanta’s
need to attract and retain senior management and key scientific
personnel; Enanta’s need to obtain and maintain patent protection
for its product candidates and avoid potential infringement of the
intellectual property rights of others; and other risk factors
described or referred to in “Risk Factors” in Enanta’s most recent
Form 10-K for the fiscal year ended September 30, 2015 and other
periodic reports filed more recently with the Securities and
Exchange Commission. Enanta cautions investors not to place undue
reliance on the forward-looking statements contained in this
release. These statements speak only as of the date of this
release, and Enanta undertakes no obligation to update or revise
these statements, except as may be required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160929006345/en/
Investor ContactEnanta Pharmaceuticals, Inc.Carol Miceli,
617-607-0710cmiceli@enanta.comorMedia ContactMacDougall
Biomedical CommunicationsKari Watson,
781-235-3060kwatson@macbiocom.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Sep 2023 to Sep 2024